Quest Diagnostics

Quest Diagnostics is an American clinical laboratory company that provides diagnostic information services to physicians, hospitals, health systems, employers, insurers, government programs, and consumers. Its testing portfolio spans routine blood and urine analysis, infectious-disease testing, cancer diagnostics, cardiovascular testing, neurological and genetic testing, pathology, toxicology, drug monitoring, and specialized testing for kidney disease and dialysis care. The company operates a large national network of patient service centers and laboratories, supplemented by hospital and health-system relationships and consumer-directed services. The business originated in 1967 as Metropolitan Pathology Laboratory, founded by physician Paul A. Brown. It became MetPath in 1969 and was acquired by Corning Glass Works in 1982, after which it operated as Corning Clinical Laboratories. Quest Diagnostics became an independent public company on December 31, 1996, when Corning spun off its clinical laboratory operations. The separation established the modern Quest identity and enabled the company to expand through acquisitions, partnerships, hospital outreach arrangements, and new testing channels. During the late 1990s, Quest acquired or integrated several laboratory operations, including a division of Diagnostic Medical Laboratory and SmithKline Beecham Clinical Laboratories. It also formed Sonora Quest Laboratories with Banner Health to serve Arizona. In 2007, the company expanded its diagnostic capabilities through the acquisition of AmeriPath, a provider focused on anatomic pathology and related services. Later agreements with health systems, retailers, insurers, and technology companies broadened access to its testing infrastructure. Quest's business model combines high-volume routine testing with specialized diagnostic services. Physicians and hospitals use its laboratories for clinical decision support, while employers and public agencies use the company for occupational, forensic, and court-ordered drug testing. QuestDirect, introduced in 2018, allows consumers to initiate selected laboratory tests without first arranging the order through a traditional physician visit, subject to applicable regulatory and clinical requirements. The company also developed a substantial COVID-19 testing operation during the pandemic, performing millions of molecular and serology tests in 2020. The brand is positioned around scale, geographic accessibility, laboratory expertise, and the practical use of diagnostic data in healthcare decisions. Its operations are primarily concentrated in the United States, with additional activity in Puerto Rico, Mexico, and Brazil and collaborative relationships involving healthcare organizations in other countries. Quest moved its headquarters from Madison, New Jersey, to Secaucus in 2018. More recent expansion has included Alzheimer's blood biomarker testing through the AD-Detect line and the acquisition of selected Spectra Laboratories assets from Fresenius Medical Care in 2025, strengthening services related to dialysis and end-stage kidney disease. Quest has also faced significant regulatory and reputational challenges. It paid substantial settlements concerning allegations involving faulty testing products, Medicare billing, Medi-Cal overcharges, and provider incentives. Its testing was among the laboratory work examined in Ireland's CervicalCheck controversy, and a breach involving a third-party collections provider exposed information associated with some Quest patients. These events illustrate the compliance, quality-control, privacy, and reimbursement risks inherent in large-scale diagnostic services. Despite these issues, Quest remains one of the largest clinical laboratory organizations in the United States and an important infrastructure provider for routine and specialized medical testing.

Quest Diagnostics traces its origins to Metropolitan Pathology Laboratory, established in 1967 by Paul A. Brown, MD. The laboratory changed its name to MetPath in 1969 and built its base in Teaneck, New Jersey. In 1982, Corning Glass Works acquired MetPath and renamed the operation Corning Clinical Laboratories. Under Corning, the laboratory business developed into a substantial provider of clinical testing and related services. On December 31, 1996, Corning spun off its clinical laboratory operations, creating Quest Diagnostics as an independent company. Kenneth W. Freeman was appointed chief executive during the transition. Quest pursued expansion soon afterward, acquiring a laboratory division of Diagnostic Medical Laboratory in 1997 and adding SmithKline Beecham Clinical Laboratories in 1999. The latter transaction included interests associated with CompuNet Clinical Laboratory and a medical sample transportation operation. In 1997, Quest and Banner Health also created Sonora Quest Laboratories, a joint venture serving Arizona. The company continued to broaden its geographic and clinical reach in the 2000s. Quest formed a strategic alliance with Ciphergen Biosystems in 2005 to commercialize proteomic tests and acquired AmeriPath in 2007, strengthening its pathology business. From 2004 to 2012, Surya Mohapatra served as president and chief executive officer. Stephen Rusckowski, previously associated with Philips Healthcare, succeeded him and led Quest through a period of network development, health-system cooperation, and consumer-access initiatives. Quest and UMass Memorial Health Care subsequently worked together to acquire a clinical outreach laboratory serving central New England. From the middle of the 2010s onward, Quest experimented with new points of access. A 2016 collaboration with Safeway introduced testing services in selected stores across several states, while a later Walmart relationship brought laboratory testing to selected stores in Texas and Florida. The company also reached an agreement to become an in-network laboratory provider for UnitedHealthcare beginning in 2019. In September 2018, Quest relocated its headquarters from Madison, New Jersey, to Secaucus. That November, it launched QuestDirect, a consumer-initiated testing service for selected health and wellness tests. The COVID-19 pandemic made Quest's laboratory infrastructure especially visible. In March 2020, the company introduced COVID-19 testing, including molecular and serology services, and reported processing millions of tests during the year. Its broader portfolio continued to include testing for cancer, cardiovascular disease, infectious diseases, neurological conditions, genetic disorders, employment screening, and court-ordered drug testing. Quest has expanded into newer biomarker and specialty areas. In 2024, it added a pTau-217 blood screening option to its AD-Detect Alzheimer's-related product line. In February 2025, it acquired selected assets of Fresenius Medical Care's Spectra Laboratories and entered a separate arrangement to provide laboratory and clinical testing services related to dialysis and end-stage kidney disease. The company's history also includes substantial compliance and quality controversies. In 2009, Quest paid $302 million to settle federal allegations concerning faulty medical testing kits. In 2011, it paid $241 million to resolve California allegations involving Medi-Cal overcharges and improper provider incentives. Quest testing was later examined in Ireland's CervicalCheck controversy over inaccurate cervical smear results. In 2019, Quest disclosed unauthorized access to information held by American Medical Collection Agency, a third-party collections provider connected through a contractor. These matters have made regulatory compliance, analytical quality, billing practices, and data security continuing issues for the brand. Today, Quest Diagnostics operates primarily in the United States, with operations or activities in Puerto Rico, Mexico, and Brazil and collaborative relationships with healthcare organizations elsewhere. Its identity is built around laboratory scale, broad test availability, patient-service-center convenience, and the conversion of diagnostic results into information used by clinicians, patients, employers, and public-health systems.

1. 2025Selected Spectra Laboratories assets are acquired

   Quest expands kidney-care and dialysis-related testing through selected assets acquired from Fresenius Medical Care's Spectra Laboratories.

   Source
2. 2024pTau-217 is added to AD-Detect

   Quest expands its Alzheimer's-related blood screening portfolio with pTau-217 testing.

   Source
3. 2020COVID-19 testing expands

   Quest launches COVID-19 molecular and serology testing and processes millions of tests during the pandemic.

   Source
4. 2018QuestDirect launches

   Quest introduces a consumer-initiated route to selected laboratory tests.

   Source
5. 2007AmeriPath is acquired

   The acquisition strengthens Quest's anatomic pathology and related diagnostic capabilities.

   Source
6. 1999SmithKline Beecham laboratory operations are added

   Quest expands through the acquisition of SmithKline Beecham Clinical Laboratories.

   Source
7. 1997Sonora Quest Laboratories is formed

   Quest and Banner Health create an Arizona laboratory joint venture.

   Source
8. 1996Quest Diagnostics becomes independent

   Corning spins off the clinical laboratory business on December 31, creating an independent Quest Diagnostics.

   Source
9. 1982Corning acquires the laboratory

   Corning Glass Works acquires MetPath and renames it Corning Clinical Laboratories.

   Source
10. 1969The business adopts the MetPath name

    Metropolitan Pathology Laboratory changes its name to MetPath and operates from Teaneck, New Jersey.

    Source
11. 1967Metropolitan Pathology Laboratory is founded

    Paul A. Brown, MD, establishes the laboratory business that later becomes Quest Diagnostics.

    Source

A large-scale, accessible diagnostic information services provider emphasizing national laboratory capacity, convenience, test breadth, and clinical support.

• Routine clinical laboratory testingClinical diagnostics1967

  Quest's core offering includes high-volume blood, urine, and other specimen testing used for routine screening, diagnosis, treatment monitoring, and preventive care. Services are ordered through physicians, hospitals, health systems, and other authorized channels and are delivered through Quest laboratories and patient service centers.

• QuestDirectConsumer health testing2018

  QuestDirect is a consumer-initiated testing service introduced in 2018. It allows customers to select certain health and wellness laboratory tests directly, after which specimens are collected through Quest's service network. Availability and test requirements vary by jurisdiction and product.

• AD-DetectNeurological and Alzheimer's testing

  AD-Detect is Quest's Alzheimer’s-related testing line. In 2024, the company added a blood screening focused on the pTau-217 protein, extending the line beyond conventional laboratory offerings into biomarker-based assessment for neurological disease research and clinical evaluation.

• COVID-19 testingInfectious-disease testing2020

  Quest introduced COVID-19 molecular and serology testing in 2020. The service supported pandemic diagnosis and antibody assessment and became one of the company's largest short-term testing programs, with millions of tests processed during the first year of widespread U.S. testing.

• Cancer and pathology diagnosticsPathology

  Quest provides pathology and cancer-related testing, including analysis of tissue and other specimens used to characterize disease and guide treatment decisions. The company's pathology capabilities were strengthened by the 2007 AmeriPath acquisition and are delivered to physicians, hospitals, and health systems.

• Employer and forensic drug testingToxicology and occupational health

  Quest performs employment, workplace, forensic, and court-ordered drug testing. These services use toxicology and specimen-validation capabilities and serve employers, government bodies, courts, and other organizations requiring standardized testing programs.

• Kidney and dialysis laboratory servicesSpecialty diagnostics2025

  Following its 2025 transaction involving selected Spectra Laboratories assets, Quest expanded its specialty testing services for dialysis providers and patients with end-stage kidney disease. The offering supports clinical monitoring and laboratory needs associated with kidney-care programs.

• 2017Walmart laboratory access partnership

  Texas · Florida

  Quest partnered with Walmart to incorporate laboratory testing into approximately 15 stores, extending the company's patient-access model into a major retail environment.

  Outcome. Established testing at selected Walmart locations.

  Source
• 2016Safeway retail testing collaboration

  United States

  Quest collaborated with Safeway to bring laboratory testing access to selected stores in California, Maryland, Virginia, Texas, and Colorado, testing a retail-oriented model for patient convenience.

  Outcome. Expanded access in selected retail locations; broader outcome not specified in the reference material.

  Source

• 2025Expand kidney-care testing through Spectra assetsM&A

  Dialysis and end-stage kidney disease require recurring, specialized laboratory monitoring.

  What changed. Quest acquired selected assets of Fresenius Medical Care's Spectra Laboratories and entered a separate agreement covering related clinical testing and laboratory services.

  Aftermath. The transaction strengthened Quest's position in dialysis and kidney-disease laboratory services.

  Source
• 2020Scale COVID-19 molecular and serology testingProduct launch

  The COVID-19 pandemic created urgent demand for diagnostic testing at national scale.

  What changed. Quest launched COVID-19 molecular and serology services and expanded laboratory capacity to process large test volumes.

  Aftermath. The company became a major U.S. testing provider during the pandemic and reported processing millions of tests in 2020.

  Source
• 2018Launch QuestDirectProduct launch

  Consumers were increasingly seeking direct and convenient access to health information and laboratory services.

  What changed. Quest introduced a consumer-initiated testing service for selected health and wellness tests.

  Aftermath. Quest added a direct-to-consumer access channel alongside physician- and institution-ordered testing.

  Source
• 2005Form a proteomics testing alliance with Ciphergen BiosystemsStrategy

  Quest sought to commercialize newer diagnostic approaches based on proteomic analysis.

  What changed. The companies formed a strategic alliance to commercialize novel proteomic tests.

  Aftermath. The alliance represented an effort to extend Quest beyond routine laboratory testing into emerging biomarker technologies.

  Source
• 1996Separate from Corning and operate independentlyStrategy

  Corning's clinical laboratory operations had developed into a substantial diagnostic business requiring an independent corporate structure.

  What changed. Corning spun off the business on December 31, 1996, creating independent Quest Diagnostics.

  Aftermath. The separation gave Quest a standalone public-company identity and a platform for acquisitions and partnerships.

  Source

• 2019Data exposure involving American Medical Collection AgencyControversy

  Quest reported that American Medical Collection Agency had experienced unauthorized access to a system containing information received from multiple entities, including information associated with Quest through a contractor relationship. AMCA subsequently filed for bankruptcy.

  Source
• 2018CervicalCheck laboratory accuracy controversyControversy

  Quest was among laboratories examined in connection with inaccurate cervical smear testing for Ireland's CervicalCheck screening program. The issue generated audits, lawsuits, and a government inquiry.

  Source
• 2011California Medi-Cal false-claims settlementControversy

  Quest paid $241 million to settle California allegations that it overcharged the Medi-Cal program and provided improper incentives to encourage healthcare-provider use of its laboratories.

  Source
• 2009Federal settlement over faulty medical testing kitsControversy

  Quest paid $302 million to the U.S. government to resolve allegations that it manufactured and distributed faulty medical testing kits. The settlement was described as the largest whistleblower-related settlement involving a medical laboratory and a faulty product at that time.

  Source

• 2025Quest acquires selected Spectra Laboratories assets

  Quest acquired selected assets from Fresenius Medical Care's Spectra Laboratories and separately agreed to provide testing services associated with dialysis and end-stage kidney disease.

  M&A
  Source
• 2024Quest adds pTau-217 blood screening to AD-Detect

  The company expanded its Alzheimer's-related testing line with a blood test intended to analyze the pTau-217 biomarker.

  Product launchProduct generation
  Source
• 2022Quest Diagnostics announces leadership transition

  Jim Davis succeeded Stephen Rusckowski as chief executive officer and chairman, marking a planned leadership transition at the public company.

  Leadership change
  Source
• 2020Quest announces COVID-19 testing service

  Quest launched molecular and serology testing during the COVID-19 pandemic and reported performing millions of tests that year.

  Product launchOther
  Source
• 2020Quest Diagnostics becomes a major commercial COVID-19 testing provider

  During the COVID-19 pandemic, Quest expanded molecular and antibody testing capacity and processed substantial volumes of SARS-CoV-2 tests for healthcare and public-health customers.

  Product launchOther
  Source
• 2018Quest becomes an in-network laboratory provider for UnitedHealthcare

  Quest announced an agreement to join UnitedHealthcare's laboratory network beginning in 2019, increasing covered-member access.

  Other
  Source
• 2018Quest launches consumer-initiated QuestDirect testing

  QuestDirect introduced a route for consumers to purchase selected health and wellness laboratory tests directly.

  Product launch
  Source
• 2017Quest and Walmart expand retail laboratory access

  Quest partnered with Walmart to provide laboratory testing at approximately 15 locations in Texas and Florida.

  Campaign
  Source
• 2016Quest and Safeway place laboratory services in selected stores

  The collaboration tested retail-based access to Quest diagnostic services in selected U.S. markets.

  CampaignOther
  Source
• 2007Quest expands pathology capabilities through AmeriPath acquisition

  Quest acquired AmeriPath, broadening its presence in anatomic pathology and physician-oriented diagnostic services.

  M&A
  Source
• 2007Quest Diagnostics completes acquisition of AmeriPath

  Quest Diagnostics completed its acquisition of AmeriPath, expanding its presence in anatomic pathology and related specialty diagnostic services.

  M&A
  Source
• 1999Quest acquires SmithKline Beecham Clinical Laboratories

  The transaction expanded Quest's laboratory network and added related operating assets and partnerships.

  M&A
  Source
• 1996Quest Diagnostics becomes an independent company through Corning spin-off

  Quest Diagnostics separated from Corning on December 31, creating an independent publicly traded clinical laboratory company.

  Other
  Source

1. Quest Diagnostics
2. Quest Diagnostics official website
3. Data breach involving Quest Diagnostics information
4. Quest Diagnostics announces leadership transition
5. Quest Diagnostics becomes a major commercial COVID-19 testing provider
6. Quest Diagnostics completes acquisition of AmeriPath